English | 繁體

Search in the results

UM

Browse/Search Results:  1-2 of 2 Help

Selected(0)Clear Items/Page:    Sort:
PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy Journal article
Lu, Dan, Xu, Zepeng, Zhang, Ding, Jiang, Min, Liu, Kefang, He, Juanhua, Ma, Dongli, Ma, Xiaopeng, Tan, Shuguang, Gao, George F., Chai, Yan. PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy[J]. Frontiers in Immunology, 2022, 13, 826045.
Authors:  Lu, Dan;  Xu, Zepeng;  Zhang, Ding;  Jiang, Min;  Liu, Kefang; et al.
Favorite | TC[WOS]:24 TC[Scopus]:27  IF:5.7/6.8 | Submit date：2022/04/06
Antibody  Cemiplimab  Immune Checkpoint Therapy (Ict)  N58 Glycosylation  Pd-1  
Identifying a role of N-glycosylation in C. elegans epithelial polarity by an RNAi-based biosynthetic-pathway-screen approach Conference paper
Zhang, H., Abraham, N., Khan, L., Zhang, N., Gobel, V.. Identifying a role of N-glycosylation in C. elegans epithelial polarity by an RNAi-based biosynthetic-pathway-screen approach[C], 2015.
Authors:  Zhang, H.;  Abraham, N.;  Khan, L.;  Zhang, N.;  Gobel, V.
Favorite |  | Submit date：2022/07/27
N-glycosylation  epithelial polarity  RNAi  biosynthetic-pathway-screen